crossing96/oncoscreening huggingface dataset:
"""Far beyond the shape"": an early head-to-head comparative urodynamic analysis of three contemporary totally intracorporeal robotic orthotopic neobladder techniques."	The expanding use of totally intracorporeal orthotopic neobladder (ICONB) reconstruction after robot-assisted radical cystectomy has fostered multiple configuration variants, yet robust comparative functional data remain limited. This early head-to-head study aimed to assess whether three contemporary ICONB configurations-Padua Ileal Neobladder, Florence Robotic Intracorporeal Neobladder (FloRIN), and a Y-shaped neobladder-deliver comparable urodynamic and continence outcomes despite anatomical nuances. Three prospectively maintained institutional cystectomy databases were merged. Patients who underwent robot-assisted radical cystectomy with ICONB and completed a standardized early multichannel urodynamic assessment were included. Cystometric capacity, compliance, residual peristaltic activity, leak point pressures, and functional continence (daytime and night-time) were compared across configurations. Functional recovery probabilities were estimated using Kaplan-Meier curves and compared with the log-rank test. Non-parametric tests were applied for other comparisons. A total of 142 patients were analyzed (Padua n = 45, FloRIN n = 49, Y-shaped n = 48). Median cystometric capacity was highest in the Padua configuration (346 mL [IQR 272-400]) versus FloRIN (269 mL [242-305]) and Y-shaped (245 mL [200-290]; p < 0.001). Compliance was most favorable in FloRIN (22 mL/cmH₂O [15-27]) compared to Padua (16 [11-41]) and Y-shaped (12 [10-19]; p = 0.029). Residual peristaltic activity and leak point pressures showed minor differences without functional impact. Daytime continence rates were similar (Padua 80%, FloRIN 83%, Y-shaped 79%; p = 0.40); night-time continence followed the same pattern (65%, 70%, 66%; p = 0.30). Kaplan-Meier curves demonstrated overlapping functional recovery trajectories (daytime p = 0.744; night-time p = 0.122). This early head-to-head comparison suggests that when core reconstructive principles are met, contemporary totally intracorporeal neobladder configurations yield distinct urodynamic profiles but comparable functional outcomes. Future efforts should define clear qualitative and temporal standards for urodynamic monitoring to support consistent functional evaluation as robotic cystectomy adoption expands.	bladder
Correction. Current status of management and outcomes of muscle-invasive bladder cancer in Yemen: a retrospective observational study.	"In the Article titled ""Current status of management and outcomes of muscle-invasive bladder cancer in Yemen: a retrospective observational study"" published on May 5, 2025, in the issue 2, vol. 97 of Archivio Italiano di Urologia e Andrologia, an author's affiliation was misspelled. In the byline, the author Faisal Ahmed's affiliation should have been ""Department of Urology, Faculty of Medicine, Sana'a University, Sana'a, Yemen"". Reference Al-Kohlany K, Al-Maleki A, Al-Shami M, Hussein H, Ahmed F. Current status of management and outcomes of muscle-invasive bladder cancer in Yemen: a retrospective observational study.  Arch Ital Urol Androl 2025;97:13760."	bladder
Incidence and risk factors for postoperative vaginal events following radical cystectomy for bladder cancer: a nationwide population-based study.	OBJECTIVE: To estimate the probability of vaginal events (diagnosis and/or surgery) following radical cystectomy (RC) and explore possible risk factors in a nationwide population-based observational registry based study. PATIENTS AND METHODS: Women undergoing RC for urinary bladder cancer in Sweden, from 1 January 1997 to 31 December 2019, were identified within national registries. Women with any postoperative vaginal event (PVE), either a diagnosis or surgical repair related to a vaginal complication, were identified using diagnostic and treatment codes. The probability of developing a PVE was estimated based on the cumulative incidence proportion using a competing risk model. Additionally, a multivariable Cox proportional hazards model was used to explore the risk factors for PVEs. Subgroup analysis was performed in patients operated from 2011 to 2019, where additional perioperative variables were registered. RESULTS: The study encompassed 1914 women with a median age of 69 years at the time of bladder cancer diagnosis. The 5-year cumulative risk of PVEs in the entire cohort was 11% (95% confidence interval [CI] 9.5-12.5%). Subgroup analysis showed that robot-assisted RC and a body mass index (BMI) >30 kg/m(2) were more often associated with PVEs after RC (hazard ratio [HR] 2.82, 95% CI 1.81-4.40; and HR 1.71, 95% CI 1.05-2.79, respectively). CONCLUSIONS: A clinically relevant cumulative incidence of PVEs following RC was identified. An association between robot-assisted RC or high BMI with increased risk of a PVE indicate the need for further studies on risk assessment of vaginal complications.	bladder
Extracellular vesicles-derived LncRNA MAFG-AS1 predicts clinical response to pembrolizumab in patients with advanced urothelial carcinoma.	BACKGROUND: Pembrolizumab is an important immune checkpoint inhibitor for advanced urothelial carcinoma (aUC). However, there are no established biomarkers to predict its efficacy. Extracellular vesicles (EVs) are liquid bilayer structures released from various cells that contain genetic information such as DNAs, RNAs, and proteins. EVs-derived long non-coding RNAs (lncRNAs) have been reported to be involved play in tumor progression and drug resistance. We investigated whether EVs-derived lncRNA MAFG-AS1 is effective in predicting pembrolizumab efficacy. METHODS: The expression of lncRNA MAFG-AS1 was examined in UC tissues from 22 patients who underwent total cystectomy at our institution, and normal urothelial tissues. Functional analysis of lncRNA MAFG-AS1 were performed using bladder cancer cell lines. The relationship between EVs-derived lncRNA MAFG-AS1 expression and clinical response and prognosis was examined in 52 patients treated with pembrolizumab. RESULTS: The expression of lncRNA MAFG-AS1 was notably higher in UC tissues than in normal urothelial tissues. LncRNA MAFG-AS1 knockdown in bladder cancer cells by siRNA, significantly decreased cell viability, invasion, and migration. Patients with a clinical response showed significantly a lower EVs-derived lncRNA MAFG-AS1 expression than those with no clinical response. The high EVs-derived lncRNA MAFG-AS1 expression group had significantly worse progression-free and overall survival than the low expression group (Log-rank P = 0.0096 and log-rank P = 0.0349, respectively). In multivariate analysis, high EVs-derived lncRNA MAFG-AS1 expression was a significant risk factor for poor clinical response to pembrolizumab (HR = 3.2, P = 0.0010). CONCLUSIONS: The EVs-derived lncRNA MAFG-AS1 may be an effective less-invasive biomarker for predicting the efficacy of pembrolizumab in aUC.	bladder
Causal insights into immune cell profiles, plasma metabolites, and bladder cancer: A Mendelian randomization approach.	This study aimed to investigate the causal associations between immune cells, plasma metabolites, and bladder cancer (BC) using Mendelian randomization (MR). Utilizing summary data from genome-wide association studies, the study examined the causal effects among 731 immune cell phenotypes, 1400 plasma metabolites, and BC. Bidirectional MR analysis was conducted to assess the links between immune cells and BC, and complemented by two-step mediation analysis and multivariate MR to identify potential mediating metabolites. Sixteen immune cell phenotypes were found to have causal associations with BC, including one with reverse causality. Additionally, 48 metabolites were identified as being causally associated with BC. Through two-step and multivariate MR analyses, 5 immune cell phenotypes and 5 plasma metabolites were identified as mediators in the causal pathway to BC. CD4+ activated cells was causally associated with BC, mediated by the unknown metabolite X-12730, with the highest mediation ratio of 11.1% CD4/CD8br showing a causal relationship with BC, mediated by choline levels, with a mediation ratio of 8.78%. CD19 on IgD- CD24- associated with BC, mediated by 4-vinylphenol sulfate levels, with a mediation ratio of 10.9%. CD19 on IgD- CD27- was linked to BC, mediated by ribitol levels, with a mediation ratio of 6.58%. CD38 on IgD+ CD24- B cells was associated with BC, mediated by pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) levels, with a mediation ratio of 6.73%. This study identified 5 immune cell phenotypes that are causally associated with BC, mediated through 5 plasma metabolites. These findings enhance our understanding of the biological pathways involved, provide potential biomarkers for identifying at-risk populations, and offer insights into strategies for early prevention and diagnosis of BC.	bladder
Integrative Analysis of Biomarkers for Cancer Stem Cells in Bladder Cancer and Their Therapeutic Potential.	Background: Cancer stem cells (CSCs) are key drivers of tumorigenesis and metastasis. However, the precise roles of CSC-associated genes in these processes remain unclear. Methods: This study integrates cancer stem cell biomarkers and clinical data from The Cancer Genome Atlas (TCGA) specific to bladder cancer (BLCA). By combining differentially expressed genes (DEGs) from TCGA-BLCA samples with CSC-related biomarkers, we conducted comprehensive functional analyses and developed an 8-gene prognostic signature through Cox regression, least absolute shrinkage and selection operator (LASSO) analysis, and multivariate Cox regression. This model was validated with GEO datasets (GSE13507 and GSE32894), and the single-cell RNA seq dataset GSE222315 was subsequently analyzed to characterize the signature genes and elucidate their interactions. And a nomogram was created to stratify TCGA-BLCA patients into risk categories. The 'oncoPredict' algorithm based on the GDSC2 dataset assessed drug sensitivity in BLCA. Result: From the TCGA cohort, 665 CSC-related genes were identified, with 120 showing significant differential expression. The 8-gene signature (ALDH1A1, CBX7, CSPG4, DCN, FASN, INHBB, MYC, NCAM1) demonstrated strong predictive power for overall survival in both TCGA and GEO cohorts, as confirmed by Kaplan-Meier and ROC analyses. The nomogram, integrating age, tumor stage and risk scores, demonstrated high predictive accuracy. Additionally, the oncoPredict algorithm indicated varying drug sensitivities across patient groups. Based on retrospective data, we identified a novel CSC-related prognostic signature for BLCA. This finding suggests that targeting these genes could offer promising therapeutic strategies.	bladder
Safety of transurethral resection of bladder tumor in octogenarians: a NSQIP analysis.	OBJECTIVES: To compare rates of 30-day post-operative complications after transurethral resection of bladder tumors (TURBT) in octogenarians versus younger patients. METHODS: We conducted a review of the NSQIP database from 2012 to 2022. We included patients undergoing TURBT as the principal procedure, and excluded patients with disseminated cancer, pre-operative sepsis, or who were ventilator-dependent. We conducted multivariate logistic regression modeling to evaluate the association of age (≥ 80 vs. < 80 years) with 30-day post-operative complications, adjusting for confounders. We report adjusted odds ratios (aOR) and 95% confidence intervals (CI). RESULTS: We identified 78,665 reports of TURBT, of which 21,627 (27.5%) were performed on patients aged ≥ 80. In multivariate analysis, age ≥ 80 was significantly associated with septic shock (aOR 2.29; 95% CI 1.44-3.66), receipt of blood transfusion ≤ 72 h (aOR 1.42; 95% CI 1.20-1.67), prolonged post-operative stay ≥ 1 day (aOR 1.50; 95% CI 1.43-1.57), unplanned related readmission (aOR 1.26; 95% CI 1.15-1.38), and death (aOR 2.74; 95% CI 2.15-3.52). Octogenarians had greater rates of readmission for hematuria (0.7% vs. 0.5%) but not reoperation for hematuria (0.7% vs. 0.8%). Octogenarians were also more frequently readmitted for severe complications (31.8% vs. 26.3% CD grades 3-5). CONCLUSIONS: Octogenarians who underwent TURBT experienced higher rates of several serious 30-day complications. While TURBT in octogenarians has a low rate of complications overall, clinicians should remain mindful of increased risk of complications for pre-operative counseling and discharge preparation.	bladder
Exploring the Effectiveness of Sitagliptin to Enhance Cisplatin Chemosensitivity in HTB-9 Bladder Cancer Cells.	Bladder cancer (BC) is a prevalent malignancy worldwide. Cisplatin (Cis)-based chemotherapy is the principal therapeutic method for many malignancies, including BC. However, side effects and resistance to Cis therapy pose significant challenges in the treatment of BC. Sitagliptin (Sita), an FDA-approved hypoglycemic drug that functions as a DPP-4 inhibitor, has recently received attention in cancer therapy. This study aimed to explore the effects of combined treatment of Cis and Sita on the BC cell line HTB-9. In this study, the IC(50) values of Sita and Cis were quantified using an MTT assay. The cells were assigned into four groups: control, Cis, Sita, and Cis + Sita. HTB-9 cells were incubated with Sita and/or Cis for 72 h. Gene expression was assessed via real-time PCR, while protein expression was evaluated by Western blot analysis. The IC(50) values for Cis and Sita were 3.01 and 543 μg/ml, respectively. Treatment of HTB-9 cells with Sita or Cis, alone or in combination, led to a significant decline in the mRNA and protein expression of proliferation-dependent markers such as AKT, PI3K, and mTOR. In addition, a notable decrease in mRNA and protein expression of the antiapoptotic marker Bcl-2 was observed in all treated groups. In contrast, the protein expression of proapoptotic markers, including Bax, Caspase-8, Caspase-3, and Caspase-7 increased after treatment with Sita and/or Cis. The findings indicated that the combination treatment with Sita and Cis had the most pronounced effect on suppressing cell proliferation and inducing apoptosis. Overall, it can be suggested that Sita may be a promising candidate for combination therapy with Cis in the treatment of BC.	bladder
LDB2 is a novel diagnostic and prognostic biomarker and inhibits bladder cancer metastasis by activating p38 MAPK/ERK1/2/JNK signaling pathway.	LIM domain binding protein 2 (LDB2), a transcriptional co-regulator of the LIM protein family, is reported to be downregulated in various tumors. However, its role in bladder cancer (BLCA) remains undefined. This study analyzed the molecular mechanism of LDB2 in inhibiting the metastasis of bladder cancer and its diagnostic and prognostic value in BLCA. We integrated The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets with enrichment analysis to evaluate the expression, diagnostic potential, and prognostic significance of LDB2 in BLCA. Immunohistochemistry (IHC) was performed to assess LDB2 expression in normal and metastatic tissues and its correlation with clinical stage and prognosis. Functional assays, including clonogenic and Transwell assays, were conducted in LDB2 knockdown and overexpression cell lines to examine its role in proliferation, migration, and invasion. Gene expression was assessed at both mRNA and protein levels using qPCR and Western blot. Additionally, CIBERSORT analysis was performed to explore the correlation between LDB2 expression and immune cell infiltration in BLCA. LDB2 expression was significantly lower in metastatic bladder cancer tissues compared with normal bladder tissues (all p < 0.001). Its expression was positively correlated with early clinical stage and favorable prognosis (all p < 0.05), Moreover, LDB2 showed strong diagnostic performance in distinguishing tumor from normal tissues, with AUC values of 0.91 (95% CI 0.86-0.96) in the TCGA cohort and 0.96 (95% CI 0.88-1.00) in the GSE37815 dataset. Furthermore, in vitro assays demonstrated that LDB2 knockdown significantly promoted invasion, metastasis, and colony formation in bladder cancer cells, whereas its overexpression suppressed these malignant behaviors. Mechanistic studies revealed that LDB2 knockdown markedly reduced the phosphorylation of key MAPK pathway components, including p38 MAPK, ERK1/2, and JNK, whereas LDB2 overexpression enhanced their phosphorylation. Immune infiltration analysis indicated that elevated LDB2 expression was associated with increased immune cell infiltration, particularly showing significant correlations with macrophages and mast cells. LDB2 may serve as a novel diagnostic biomarker and tumor suppressor by inhibiting proliferation, invasion, and metastasis via activation of the p38 MAPK/ERK1/2/JNK pathway and modulating the tumor immune microenvironment.	bladder
Investigating the relationship between peripheral blood transferrin receptor protein and tumor cell ferroptosis, invasion, and metastasis in bladder cancer.	This study aimed to investigate the relationship between peripheral blood transferrin receptor protein (TfR) and tumor cell ferroptosis, as well as bladder cancer invasion and metastasis, and further reveal the mechanism of action of TfR in bladder cancer progression. Fifteen patients with bladder cancer, treated at the Department of Urology in our hospital from February 2022 to August 2023, were recruited as research subjects. The patients were aged between 44 and 68 years, with an average age of 52.57 ± 4.38 years. General patient data were analyzed, and the level of peripheral blood TfR was detected at baseline (T0), 3 months (T1), 6 months (T2), and 9 months (T3) post-treatment using a repeated measures design. The levels of GPX4, Ferroportin, and transferrin receptor in the peripheral blood were measured by enzyme-linked immunosorbent assay (ELISA) at T0, T1, T2, and T3. Tumor size and invasiveness were assessed using MRI imaging at the same time points. Protein expressions of MMP-2, MMP-9, and N-Cadherin were analyzed by Western blot at T0, T1, T2, and T3. Pearson correlation analysis was utilized to examine the relationship between TfR, GPX4, Ferroportin, transferrin receptor levels, and tumor invasion and metastasis. As treatment progressed, TfR levels at T3 and T2 were significantly lower than those at T1 and T0 (P < 0.05). Similarly, markers of tumor cell ferroptosis (GPX4, Ferroportin, and transferrin receptor) also showed significant decreases (P < 0.05). Tumor volume at T3 was smaller compared to T0, T1, and T2 (P < 0.05). The protein expressions of MMP-2, MMP-9, and N-Cadherin at T3 and T2 were significantly lower than those at T0 and T1 (P < 0.05). Increased peripheral blood TfR levels and reduced tumor cell ferroptosis were associated with higher cancer cell invasion and metastasis. A reduction in peripheral blood TfR levels is associated with the effectiveness of bladder cancer treatment. This reduction may decrease the invasiveness and migration ability of cancer cells by affecting the iron metabolism pathway. These findings may provide a basis for the development of new targeted therapeutic strategies to improve outcomes for patients with bladder cancer.	bladder
Prevalence of therapeutic or disease-relevant oncogenic alterations: An analysis of the AACR Project GENIE Biopharma Cooperative bladder cancer cohort.	PURPOSE: This study reports the real-world prevalence of therapeutic and/or disease-relevant oncogenic alterations in cancer research, specifically in the bladder cancer cohort of the American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC). METHODS: The GENIE BPC bladder cancer cohort (v1.1) included adult patients with bladder cancer with genomic sequencing results reported between January 1, 2013, and December 31, 2018. The prevalence of alterations in PPARG, KRAS, TP53, FGFR3, ERBB2, ERBB3, EGFR, MET, B7-H3, and GPC3 was evaluated descriptively in the overall cohort and by stage of disease, patient demographics, and clinical characteristics. RESULTS: The study included 716 patients. Median age at sequencing was 67.8 years; most patients were male (76.5%) and non-Hispanic White (82.0%) and had a reported history of urothelial carcinoma (96.2%). The prevalence was 54.3% (95% CI: 50.6-58.0) for TP53 mutations, 4.3% (95% CI: 3.0-6.1) for KRAS hotspot mutations, 13.4% (95% CI: 11.0-16.1) for FGFR3 activating mutations, and 12.1% (95% CI: 9.7-14.9) for any PPARG amplification. Overall, prevalence of gene alterations was similar between patients with stage I-III disease and advanced or metastatic disease and across subgroups based on patient demographics and clinical characteristics. CONCLUSIONS: The prevalence of gene alterations is consistent with ranges reported in the literature. This analysis provides insights into the distribution of therapeutic or disease-relevant genetic biomarkers in patients with bladder cancer and helps the understanding of patient biomarker profile to support clinical development for patients with bladder cancer.	bladder
A urinary DNA methylation assay using two genes enables noninvasive detection and prognostic prediction in urothelial carcinoma.	The incidence of urothelial carcinoma (UC) ranks second among all urological cancers, accounting for over 90% of malignant tumors in bladder. Patients diagnosed with UC experience a lower quality of life due to rapid progression of the disease. Early and non-invasive detection is curial for diagnosing UC and improving patient outcomes. This study aimed to develop and validate a DNA methylation assay for the early detection and monitoring for UC, with a focus on its diagnostic and prognostic implications. The DNA methylation assay with real-time methylation specific polymerase chain reaction (RT-MSP) technique measures the methylation level of SOX1-OT and HIST1H4F in urine samples. A cohort comprising 436 patients diagnosed with UC or other urologic disease as well as 79 healthy patients was retrospectively utilized to evaluate this assay. Furthermore, UC patients who underwent surgery are included to assess its ability to detect recurrence. The DNA methylation assay demonstrated significantly increased methylation level in tumor tissues and a high positive rate in urine samples from UC patients. The methylation profile effectively distinguishes UC from other non-UC urologic disease, exhibiting a high sensitivity (85.2%) and specificity (90.0%) for UC diagnosis. Furthermore, the assay showed promising ability in differentiating UC patients based on tumor grade, malignancy potential, and disease stage. Additionally, the DNA methylation assay demonstrated a superior ability to detect UC recurrence with a high area under curve (AUC) of 0.979. This research proposes a novel DNA methylation assay with urine as sample for detection, representing a cost-efficient and non-invasive method for diagnosing and monitoring UC disease.	bladder